The global market for Knock Out Mouse Model was valued at US$1.3 Billion in 2025 and is projected to reach US$1.8 Billion by 2032, growing at a CAGR of 4.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Recent advancements have led to the development of sophisticated conditional and inducible KO models, wherein gene silencing can be restricted to specific tissues or timeframes. This granularity is vital for dissecting gene functions that may be lethal if knocked out systemically. Such refinements have expanded the applicability of KO mice beyond early developmental studies into aging, regenerative biology, and chronic disease modeling. Additionally, innovations in high-throughput gene editing and sequencing are enabling the generation of large-scale KO mouse libraries, further accelerating genotype-to-phenotype correlations. The availability of global initiatives like the International Knockout Mouse Consortium (IKMC) and the Knockout Mouse Project (KOMP) is helping centralize resources and democratize access, thus scaling research across academia and biotech sectors.
High-throughput pipelines and automation technologies are also transforming KO mouse production. Facilities equipped with robotic microinjection systems, automated embryo transfer, and digital phenotyping platforms are shortening lead times and increasing model reproducibility. Furthermore, the integration of artificial intelligence into phenotypic screening is allowing for faster identification of observable traits, thereby enhancing throughput in both discovery and validation phases. CROs and contract breeding companies are increasingly offering off-the-shelf and custom KO models, often bundled with phenotypic validation, housing, and tissue collection services, which are streamlining R&D workflows for pharmaceutical companies and academic researchers alike.
The demand for conditional and tissue-specific KO models is growing in tandem with advancements in promoter design and inducible recombination systems, such as Cre-loxP and FLP/FRT. These models are instrumental in overcoming embryonic lethality and studying gene function in postnatal physiology or adult disease states. Additionally, dual recombinase systems are gaining traction for their ability to study gene-gene interactions and pathway cross-talk in a controlled environment, further enriching the functional genomics toolbox.
Academic institutions, government-funded initiatives, and pharmaceutical companies are all scaling investments in KO model infrastructure. Centralized mouse repositories and breeding facilities are helping standardize protocols and ensure reproducibility. Meanwhile, the increasing emphasis on open science and data sharing is leading to public repositories of KO strain phenotypic data, facilitating cross-laboratory collaboration. Initiatives like the European Mouse Mutant Archive (EMMA) and the Mouse Genome Informatics (MGI) platform provide searchable databases for researchers worldwide, allowing access to annotated KO lines, phenotypic data, and breeding protocols.
Another key trend is the growing reliance on KO models in drug repositioning and toxicogenomics. By knocking out drug target genes in preclinical models, researchers can determine potential off-target effects, elucidate compensatory pathways, and improve early attrition rates. Regulatory bodies, too, are recognizing the value of KO models in toxicology packages and are encouraging their use in safety pharmacology and biomarker validation. Increasing demand from regulatory science, coupled with the growing availability of tailored KO services, is significantly expanding the commercial opportunity for service providers in this space.
Technological advances in embryo manipulation, stem cell culturing, and in vivo imaging are enabling faster model generation and longitudinal monitoring, which are improving the efficiency and relevance of preclinical trials. Commercial CROs and transgenic service providers are scaling operations to cater to growing client demand, particularly in Asia-Pacific and North America. Moreover, as pharmaceutical firms adopt target deconvolution and pathway elucidation strategies earlier in the discovery phase, KO models are being positioned as essential inputs in the design of first-in-class molecules. The global rise in biologics and gene therapies is further reinforcing the demand for precise animal models that replicate human gene expression environments.
Government funding and public-private partnerships continue to play a vital role in sustaining the KO model ecosystem. National biobanks, model organism consortia, and translational research centers are driving KO adoption by integrating them into multi-omics pipelines that combine genomics, transcriptomics, and metabolomics. As ethical concerns and animal welfare regulations become more stringent, there is also a shift toward reducing, refining, and replacing animal use-leading to smarter study designs where KO models are used more judiciously and efficiently. Together, these scientific, commercial, and regulatory forces are underpinning sustained growth and innovation in the knock out mouse model market.
Global Knock Out Mouse Model Market - Key Trends & Drivers Summarized
Why Are Knock Out Mouse Models Considered Indispensable Tools in Biomedical Research?
Knock out (KO) mouse models have become indispensable assets in translational and fundamental biomedical research due to their ability to elucidate gene function by completely inactivating specific genes. These models offer researchers a powerful platform to study the physiological consequences of gene deletion, providing insight into disease mechanisms, drug targets, and therapeutic pathways. Since the introduction of gene targeting techniques via homologous recombination in embryonic stem cells, KO mouse models have evolved into essential tools for modeling monogenic diseases, cancer, immunological disorders, and metabolic syndromes. Their genetic manipulability and physiological resemblance to humans make them especially valuable in preclinical validation and toxicological studies.Recent advancements have led to the development of sophisticated conditional and inducible KO models, wherein gene silencing can be restricted to specific tissues or timeframes. This granularity is vital for dissecting gene functions that may be lethal if knocked out systemically. Such refinements have expanded the applicability of KO mice beyond early developmental studies into aging, regenerative biology, and chronic disease modeling. Additionally, innovations in high-throughput gene editing and sequencing are enabling the generation of large-scale KO mouse libraries, further accelerating genotype-to-phenotype correlations. The availability of global initiatives like the International Knockout Mouse Consortium (IKMC) and the Knockout Mouse Project (KOMP) is helping centralize resources and democratize access, thus scaling research across academia and biotech sectors.
How Are CRISPR and High-Throughput Engineering Reshaping Model Development?
The advent of CRISPR/Cas9 technology has significantly lowered the time and cost required to generate KO mouse models, thereby democratizing their use across smaller labs and commercial CROs. Traditional homologous recombination techniques, which could take up to a year to develop a stable KO line, have now been supplemented or replaced by CRISPR-based systems that enable precise, site-specific gene disruption in a fraction of the time. Multiplex gene editing-targeting multiple genes simultaneously-is increasingly being used to model complex, polygenic diseases such as diabetes, Alzheimer’s, and autoimmune conditions, offering new avenues for precision medicine research.High-throughput pipelines and automation technologies are also transforming KO mouse production. Facilities equipped with robotic microinjection systems, automated embryo transfer, and digital phenotyping platforms are shortening lead times and increasing model reproducibility. Furthermore, the integration of artificial intelligence into phenotypic screening is allowing for faster identification of observable traits, thereby enhancing throughput in both discovery and validation phases. CROs and contract breeding companies are increasingly offering off-the-shelf and custom KO models, often bundled with phenotypic validation, housing, and tissue collection services, which are streamlining R&D workflows for pharmaceutical companies and academic researchers alike.
The demand for conditional and tissue-specific KO models is growing in tandem with advancements in promoter design and inducible recombination systems, such as Cre-loxP and FLP/FRT. These models are instrumental in overcoming embryonic lethality and studying gene function in postnatal physiology or adult disease states. Additionally, dual recombinase systems are gaining traction for their ability to study gene-gene interactions and pathway cross-talk in a controlled environment, further enriching the functional genomics toolbox.
Which Research Domains and Institutional Trends Are Driving Model Utilization?
The utilization of KO mouse models is seeing rapid growth across oncology, neurology, immunology, and metabolic research domains. In cancer biology, KO mice are used extensively to validate tumor suppressor genes, study oncogene function, and model resistance mechanisms to targeted therapies. Researchers are creating isogenic KO mouse strains with humanized immune systems to evaluate tumor-immune interactions and the efficacy of immuno-oncology candidates. In neuroscience, KO models are being leveraged to study gene involvement in neurodevelopmental and neurodegenerative disorders such as autism, Parkinson’s disease, and epilepsy, particularly through region-specific gene inactivation.Academic institutions, government-funded initiatives, and pharmaceutical companies are all scaling investments in KO model infrastructure. Centralized mouse repositories and breeding facilities are helping standardize protocols and ensure reproducibility. Meanwhile, the increasing emphasis on open science and data sharing is leading to public repositories of KO strain phenotypic data, facilitating cross-laboratory collaboration. Initiatives like the European Mouse Mutant Archive (EMMA) and the Mouse Genome Informatics (MGI) platform provide searchable databases for researchers worldwide, allowing access to annotated KO lines, phenotypic data, and breeding protocols.
Another key trend is the growing reliance on KO models in drug repositioning and toxicogenomics. By knocking out drug target genes in preclinical models, researchers can determine potential off-target effects, elucidate compensatory pathways, and improve early attrition rates. Regulatory bodies, too, are recognizing the value of KO models in toxicology packages and are encouraging their use in safety pharmacology and biomarker validation. Increasing demand from regulatory science, coupled with the growing availability of tailored KO services, is significantly expanding the commercial opportunity for service providers in this space.
What Is Fueling the Growth Trajectory of the Knock Out Mouse Model Market?
The growth in the global knock out mouse model market is driven by several factors, including the accelerated adoption of CRISPR gene editing, rising research activity in precision medicine, and growing demand for humanized and tissue-specific animal models. The expanding prevalence of chronic and rare diseases has intensified the search for functional genomics tools that offer mechanistic insights into gene-disease relationships. KO mouse models are playing a central role in this effort by serving as in vivo validation platforms for novel targets and biomarkers, particularly in oncology and neurological research pipelines.Technological advances in embryo manipulation, stem cell culturing, and in vivo imaging are enabling faster model generation and longitudinal monitoring, which are improving the efficiency and relevance of preclinical trials. Commercial CROs and transgenic service providers are scaling operations to cater to growing client demand, particularly in Asia-Pacific and North America. Moreover, as pharmaceutical firms adopt target deconvolution and pathway elucidation strategies earlier in the discovery phase, KO models are being positioned as essential inputs in the design of first-in-class molecules. The global rise in biologics and gene therapies is further reinforcing the demand for precise animal models that replicate human gene expression environments.
Government funding and public-private partnerships continue to play a vital role in sustaining the KO model ecosystem. National biobanks, model organism consortia, and translational research centers are driving KO adoption by integrating them into multi-omics pipelines that combine genomics, transcriptomics, and metabolomics. As ethical concerns and animal welfare regulations become more stringent, there is also a shift toward reducing, refining, and replacing animal use-leading to smarter study designs where KO models are used more judiciously and efficiently. Together, these scientific, commercial, and regulatory forces are underpinning sustained growth and innovation in the knock out mouse model market.
Report Scope
The report analyzes the Knock Out Mouse Model market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:- Segments: Type (Constitutive Knockout Mouse, Conditional Knockout Mouse, Protein Function Knockout Mouse); Application (Oncology Application, Neurology Application, Cardiovascular Application, Other Applications); End-User (Clinical Research Organizations End-User, Pharma & Biotechnology Companies End-User, Other End-Users)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Constitutive Knockout Mouse segment, which is expected to reach US$956.2 Million by 2032 with a CAGR of a 4.4%. The Conditional Knockout Mouse segment is also set to grow at 5.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $361.8 Million in 2025, and China, forecasted to grow at an impressive 7.9% CAGR to reach $378.8 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Knock Out Mouse Model Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Knock Out Mouse Model Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Knock Out Mouse Model Market expected to evolve by 2032?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2032?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Biocytogen, Charles River Laboratories, Cyagen Biosciences, genOway, GemPharmatech and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the companies featured in this Knock Out Mouse Model market report include:
- Biocytogen
- Charles River Laboratories
- Cyagen Biosciences
- genOway
- GemPharmatech
- Harbour BioMed
- Horizon Discovery (Revvity)
- Ingenious Targeting Laboratory
- Inotiv
- JAX (The Jackson Laboratory)
- KOMP Repository (MMRRC UC Davis)
- Merck KGaA
- Nanjing Galaxy Biopharma
- Ozgene
- PolyGene
- Shanghai Model Organisms Center
- Taconic Biosciences
- TransCure bioServices
- Transgenic Inc.
- Yecuris Corporation
What Sets This Report Apart From Others?
- Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
- Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
- Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
- Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
- Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
- Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biocytogen
- Charles River Laboratories
- Cyagen Biosciences
- genOway
- GemPharmatech
- Harbour BioMed
- Horizon Discovery (Revvity)
- Ingenious Targeting Laboratory
- Inotiv
- JAX (The Jackson Laboratory)
- KOMP Repository (MMRRC UC Davis)
- Merck KGaA
- Nanjing Galaxy Biopharma
- Ozgene
- PolyGene
- Shanghai Model Organisms Center
- Taconic Biosciences
- TransCure bioServices
- Transgenic Inc.
- Yecuris Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 368 |
| Published | October 2026 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 1.3 Billion |
| Forecasted Market Value ( USD | $ 1.8 Billion |
| Compound Annual Growth Rate | 4.6% |
| Regions Covered | Global |
